Literature DB >> 17278385

Pathogenesis of avian flu H5N1 and SARS.

Malik Peiris1.   

Abstract

Avian influenza A (H5N1) and severe acute respiratory syndrome (SARS) coronavirus are infections that cause a severe viral pneumonia leading to acute respiratory dysfunction syndrome and carry a high case-fatality rate. We have investigated innate immune responses to both viruses using primary human macrophages and respiratory epithelial cells as in vitro models. In contrast to human influenza A H1NI viruses, the H5N1 viruses hyper-induce cytokines (tumour necrosis factor [TNF]alpha, interferon beta) and chemokines (IP10, MIP1alpha, MCP) in in vitro cultures of primary human macrophages. A similar differential effect is observed in primary human bronchial epithelial cells and in type 2 pneumocytes although TNFalpha is not induced in respiratory epithelial cells. The cell signalling pathways responsible for this differential effect remain to be explored. Preliminary data suggest that such differential signalling involves p38 MAP kinase rather than NF-kappaB. SARS coronavirus infection of primary human macrophages is associated with a strong induction of chemokines without an associated type 1 interferon response. These observations may be relevant in disease pathogenesis.

Entities:  

Mesh:

Year:  2006        PMID: 17278385

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  12 in total

1.  Early control of H5N1 influenza virus replication by the type I interferon response in mice.

Authors:  Kristy J Szretter; Shivaprakash Gangappa; Jessica A Belser; Hui Zeng; Hualan Chen; Yumiko Matsuoka; Suryaprakash Sambhara; David E Swayne; Terrence M Tumpey; Jacqueline M Katz
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

2.  H5N1, a wealth of knowledge to improve pandemic preparedness.

Authors:  Daniel R Perez; Adolfo Garcia-Sastre
Journal:  Virus Res       Date:  2013-12-05       Impact factor: 3.303

Review 3.  The pathology of influenza virus infections.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 4.  Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules.

Authors:  David Marsolais; Hugh Rosen
Journal:  Nat Rev Drug Discov       Date:  2009-03-20       Impact factor: 84.694

5.  Immunomorphologic manifestations in mice liver infected with influenza A/H5N1, A/goose/Krasnoozerskoye/627/05 strain.

Authors:  Oxana V Potapova; Tatyana V Sharkova; Vyacheslav A Shkurupiy; Alexander M Shestopalov
Journal:  Clin Dev Immunol       Date:  2013-12-23

6.  A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.

Authors:  Liang Chen; Chun Hu; Molly Hood; Xue Zhang; Lu Zhang; Juntao Kan; Jun Du
Journal:  Nutrients       Date:  2020-04-24       Impact factor: 5.717

7.  CAPIH: a Web interface for comparative analyses and visualization of host-HIV protein-protein interactions.

Authors:  Fan-Kai Lin; Chia-Lin Pan; Jinn-Moon Yang; Trees-Juen Chuang; Feng-Chi Chen
Journal:  BMC Microbiol       Date:  2009-08-12       Impact factor: 3.605

8.  Avian influenza virus H5N1 induces rapid interferon-beta production but shows more potent inhibition to retinoic acid-inducible gene I expression than H1N1 in vitro.

Authors:  Zhiqiang Mi; Yonghong Ma; Yigang Tong
Journal:  Virol J       Date:  2012-08-03       Impact factor: 4.099

9.  Association between the Severity of Influenza A(H7N9) Virus Infections and Length of the Incubation Period.

Authors:  Victor Virlogeux; Juan Yang; Vicky J Fang; Luzhao Feng; Tim K Tsang; Hui Jiang; Peng Wu; Jiandong Zheng; Eric H Y Lau; Ying Qin; Zhibin Peng; J S Malik Peiris; Hongjie Yu; Benjamin J Cowling
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

Review 10.  An overview of the highly pathogenic H5N1 influenza virus.

Authors:  Jingchuan Yin; Shi Liu; Ying Zhu
Journal:  Virol Sin       Date:  2013-01-16       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.